Trajkova, Sanja
Preferred name
Trajkova, Sanja
Official Name
Trajkova, Sanja
Main Affiliation
114 results
Now showing 1 - 10 of 114
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Extranodal Diffuse Large B-Cell Lymphoma of the Small Bowel in Female Patient Causing Intestinal Obstruction: A Case Report(Vilnius University Press, 2022-12-30); ; ; Diffuse large B cell lymphoma is the most common extranodal non-Hodgkin lymphoma of the small intestine accounting for more than 50% of cases. Forty percent of these cases initially present with small bowel obstruction. Therefore, the diagnosis is usually established after surgery for bowel obstruction. The treatment is then continued with a certain chemotherapy regimens. We present a case of a 46-years-old female patient with signs of small bowel obstruction due to previously undiagnosed diffuse large B-cell lymphoma. Postoperatively, the patient was treated with 7 cycles of R-CHOP protocol and complete response was achieved in the short follow-up period.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P062 Results of RCHOP6 or RCHOP8 study in the treatment of patients with diffuse large B-cell lymphoma – single institution study(Elsevier BV, 2007-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Poster: AML-327: Plasmacytoid Dendritic Cell Proliferation Associated with Acute Myeloid Leukemia: A Case Report(Elsevier BV, 2021-09); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Прогностичко одредување на исходот од лекување со автологна трансплантација на матични хематопоетски клетки(SHMSHM - AAMD, 2012); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, IMPACT OF INITIAL RENAL INVOLVEMENT AND BENCE JONES PROTEINS IN THE URINE ON OVERALL SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA(Macedonian Association of Anatomists, 2022); ; ; ; Ridova, Nevenka - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cryopreservation of autologous peripheral blood stem cells - presence and future directions(Macedonian Association of Anatomists and Morphologists, 2015); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CML-053 Health-Related Quality of Life in Macedonian Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: EQ-5D-5L Assessment(Elsevier BV, 2024-09); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hematologic Autoimmune Manifestation Secondary to Coronavirus Disease 19 Infection – A Single-Center Experience(Scientific Foundation SPIROSKI, 2021-09-11); ; ; <jats:p>Introduction: Since December 2019, multiple human cases of novel coronavirus infection were reported, representing with upper respiratory symptoms (influenza-like presentation). The virus was named the Severe acute respiratory system coronavirus 2 (SARS-COV-2). Studies have reported cases of patients with COVID-19 infection, including development of several autoimmune events that suggests that infection with SARS CoV-2 may be associated with initiation of autoimmune hematological autoimmune disorders. Aim: Review the hematological autoimmune phenomenon after infection with SARS-COV-2 in order to assist into the pathogenic mechanisms, clinical manifestations and treatment of this group of patients. Materials and methods: This is a retrospective study that includes 21 patients with autoimmune diseases like secondary immune thrombocytopenia (ITP), autoimmune hemolytic anemia( AIHA) and thrombotic thrombocytopenic purpura (TTP) that have emerged after COVID-19 infection. The patients were diagnosed and treated at the University Clinic of Hematology for a period of time from January 2020 to April 2021. Results: The most common hematologic autoimmune disorder was ITP in 13 cases (62%) followed by AIHA in 5 cases (24%) and TTP in 3 individuals (14%). The mean time of onset of the hematologic auto-immune presentations was 18,4 ± 10,3 days. The therapy of this conditions in patients with COVID-19 infection requires an individualized approach to achieve a precise balance between the risk of severe bleeding and of thromboembolic events. Conclusion: Causal relationship between COVID-19 infection and these autoimmune events still requires further studies. We should all have in mind the risk of development of hematologic autoimmune disorders in infected patients. </jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P095 Long term follow up of autologous transplant in AML patients in first complete remission(Elsevier BV, 2007-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Rare Case of Soft Tissue Erdheim Chester Disease: Diagnostic Dilemma and Management(2019-06-15); ; ; Background: Erdheim Chester disease (ECD) is a rare form of non-Langerhans histiocytosis that still presents a diagnostic and clinical dilemma. Case presentation: We present a rare case of ECD, young 31 male with atypical localisation and soft tissue presentation and no bone involvement. He started clinical investigations due to subcutaneous tumour mass in the lumbar spine that caused severe back pain. Skin biopsy revealed ECD with Immunohistochemistry CD68+, CD10+, CD11c+, vimentin+, S100A4+. Activating BRAFV600E mutation was positive from the tumour tissue. The patient was referred to the haematology department. PET CT was performed for initial disease staging. Treatment was started with corticosteroids (methylprednisolone 0.5 mg/kg per day), and after 7 days, a significant clinical improvement was noticed in terms of pain disappearance with no need for pain killers. After two weeks, treatment with interferon Alfa (IFN-α) was started in a dose of 3 million units 3 times per week. After 4 months of interim treatment PET, CT revealed a significant reduction of the tumour mass. Therapy with IFN-α was continued, and the patient is still clinically in good condition. Conclusion: It can be concluded that shortening the time of diagnosis of ECD is essential in treatment outcome of this disease. Still, large studies have to confirm the best treatment of this rare condition.